Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess clemastine as a remyelinating agent in patients
with acute optic neuritis.The study will also evaluate the tolerability of clemastine,
originally approved as first-generation antihistamine, in patients with optic neuritis. Study
procedures will include assessments for evidence of remyelination in the anterior visual
pathway and in the brain using electrophysiologic techniques and magnetic resonance imaging.
If they are on one, patients in this study can remain on their standard disease modifying
treatment during the course of the study. However, patients cannot participate in any other
investigational new drug research study concurrently.